Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

(MedPage Today) -- At the recent American Society of Hematology (ASH) annual meeting, updated data on mosunetuzumab (Lunsumio) in relapsed/refractory follicular lymphoma revealed durable responses, particularly in high-risk patients.
In this first...